Tania A. Thomas

Tania A. Thomas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tania A. Thomas has a total of 177 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Nanoparticle capture of urinary lipoarabinomannan for diagnosing childhood tuberculosis

    by Kumail Ahmed, Brendan T. Mullen, Najeeha T. Iqbal, Tania A. Thomas

    Urinary assays detecting lipoarabinomannan (LAM) as a diagnostic test for tuberculosis (TB) have limited sensitivity in pediatric populations. We aimed to evaluate the Ceres TB-Nanotrap to concentrate LAM and augment detection in urine using the Alere lateral flow assay (LF-LAM). This case-control study recruited 32 children with and without TB aged 1–18 years in Karachi, Pakistan, with banked urine specimens. TB case participants were classified as confirmed or unconfirmed TB using modified National Institutes of Health (NIH) consensus criteria. The LF-LAM test was performed before and after concentrating 5 mL of urine with TB-Nanotrap particles. Band intensity was measured via visual grading and digital quantification. Urine LAM sensitivity by visual grading was 4.5% (95% confidence interval [CI] 0.3–18.5) pre-concentration and 50.0% (95% CI 30.0–70.0) post-concentration. Sensitivity by digital quantification was 0.0% (95% CI 0.0–15.4) pre-concentration and 63.9% (95% CI 42.8–81.4) post-concentration. Specificity was high with both methods (visual grading: 90.0% [95% CI 62.8–99.4] pre-concentration and 90.0% [95% CI 62.8–99.4] post-concentration; digital analysis: 80.0% [95% CI 44.4–97.5] and 90.0% [95% CI 62.8–99.4], respectively). For cases, digital analysis showed an increase in median LF-LAM band intensity from 0.0 arbitrary units (AU) (interquartile range [IQR] 0.00–32.5) in unconcentrated samples to 98.4 AU (IQR 34.9–212.2) in concentrated samples. Concentration with TB-Nanotrap greatly increased sensitivity of urine LAM detection without a change in specificity. Use of TB-Nanotrap and digital quantitative analysis of urine LAM improved the diagnostic accuracy of the LF-LAM assay in this pediatric population and should be validated in larger studies. IMPORTANCE: Diagnosing TB in children is challenging due to a lack of accurate and accessible diagnostic tests. In this study, we evaluated two methods of improving detection of TB in children using a commercially available urine test. First, we processed the urine to concentrate any available TB antigens. Second, we included a digital reader to interpret the test results. We found that concentrating urine and using a digital reader led to an increase in TB detection among children who had been diagnosed with TB, while minimizing false-positive results among children who did not have TB.

  • Open Access

    Tuberculosis prevalence among children with severe acute malnutrition: a systematic review and meta-analysis

    by Aleezay A. Khan, Jasmine Armour-Marshall, Muhammad Bashir Abdullahi, Lawan Bukar, Cécile Cazes, Chishala Chabala, Mohammod Jobayer Chisti, Moussa Mamane Oumarou Farouk, Anthony J. Garcia-Prats, Catherine Hewison, et al.

    Introduction: Control of tuberculosis (TB) in children remains a major challenge globally. There is growing recognition that children with severe acute malnutrition (SAM) are a high-risk population for TB, but the global burden of TB in this group has never been comprehensively quantified. Methods: We conducted a systematic review and meta-analysis to estimate the prevalence of TB among children with SAM. Following PRISMA guidelines, we searched PubMed/MEDLINE, Embase, Scopus, Web of Science, Cochrane Library, and WHO Global Index Medicus from database inception to June 15, 2026. We included studies reporting TB among systematically sampled cohorts of children <15 years with SAM as defined by the World Health Organization. Methodological study quality was assessed with adapted versions of the Newcastle-Ottawa Scale or the Joanna Briggs Institute critical appraisal checklist. Pooled TB prevalence was calculated using a random-effects model with predefined stratification of studies by geographic region, national TB incidence, and study quality. We also conducted subgroup analyses by age, sex, HIV status, SAM type, and TB exposure. Results: We included 73 studies comprising 33,869 children with SAM across 15 countries, predominantly from sub-Saharan Africa and South Asia, and predominantly reporting on hospitalized children. The pooled TB prevalence was 13% (95% CI: 11-16%), but there was substantial heterogeneity (I²=98%). Studies conducted in Southern Africa had the highest pooled TB prevalence (36%, 95% CI: 19-56%) compared to other regions (p<0.01). Pooled TB prevalence was higher in those with history of TB household exposure compared to those without (74% vs. 17%, p=0.01). Conclusions: Approximately one in eight children hospitalized with SAM have TB, greatest among children with history of TB exposure and those in Southern Africa. These findings highlight opportunities for improved early TB diagnosis and routine, integrated TB screening within hospital-based SAM care pathways.

  • Efficacy of isoniazid in paediatric tuberculosis: an individual participant data meta-analysis

    by Agathe Béranger, Belén P. Solans, Ryo Miyakawa, Helen McIlleron, Joel Tarning, Ira Shah, Blessed Winston Aruldhas, Binu Susan Mathew, Awewura Kwara, Charles A. Peloquin, et al.

    Background: Isoniazid is a cornerstone of management therapy for tuberculosis (TB). Our aim was to determine the association between isoniazid exposure and clinical outcomes, to develop a pharmacokinetic model, and to optimise the dosing regimen in children treated for drug-susceptible (DS)-TB. Methods: For this individual participant data meta-analysis, PubMed was searched for observational studies, involving children (aged 0–18 years), being treated for DS-TB. The relationship between isoniazid exposure and clinical outcomes was analysed using a mixed effects logistic regression model. Pharmacokinetic parameters were described using non-linear mixed effects modelling. The pharmacokinetic target was the median adult area under the concentration–time curve at steady-state (AUC ss ) of 23.4 mg·h·L −1 . Results: Six studies provided clinical outcomes, including 405 patients, of which 21% had unfavourable outcomes. 16 studies (1255 patients) were included in the pharmacokinetic model. Unfavourable outcomes were only related to lower body mass index (BMI) for age z-score (BAZ) (OR 0.96, 95% CI 0.93–0.99; pN -acetyltransferase 2 (NAT2) genotype, weight, age and nutritional status (using BAZ). With currently recommended World Health Organization (WHO) doses, isoniazid exposure was similar to that of adults. Pharmacokinetic target attainment was 71.7% and 29.5% for slow and fast metabolisers, respectively (p0 and 42.6% for malnourished patients (BAZ < −2) (p<0.05). The model-informed dosing regimen showed that fast metabolisers could benefit from higher isoniazid dosing, especially in malnourished children. Conclusion: Our findings showed that the only predictor of unfavourable clinical outcomes was a lower BAZ. We support the current WHO-recommended dosing regimen for isoniazid. To equalise and attain our pharmacological target for all children, dosing regimens could be adjusted on NAT2 genotype and nutritional status.


  • Open Access

    A narrative review of the pathophysiology of sepsis in sub-Saharan Africa: Exploring the potential for corticosteroid therapy

    by Phoebe Gruccio, William S. Girard, Amelia D. Badipour, Reagan Kakande, Victor Adejayan, Muhammad Zulfiqar, Michael Ndyomugabe, Philemon Ojuman, Scott K. Heysell, Megan Null, et al.

    Sepsis remains a significant global health threat with a disproportionate burden in low-income countries including those in sub-Saharan Africa where case fatality rates are as high as 30% to 50%. Defined as a severe systemic response to infection, sepsis leads to widespread immune dysregulation and organ dysfunction, including adrenal insufficiency. Critical illness-related corticosteroid insufficiency (CIRCI) arises from dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis, altered cortisol metabolism, and tissue resistance to glucocorticoids, all of which can occur during sepsis. Clinical trials of corticosteroids for the treatment of patients with sepsis and septic shock have shown improvements in shock reversal, and in some studies, patient survival; however, their role in the treatment of sepsis in sub-Saharan Africa is unknown. The incidence of sepsis in sub-Saharan Africa is compounded by high rates of human immunodeficiency virus (HIV) and co-infections, including tuberculosis (TB), which is the leading cause of sepsis. Both HIV and TB can cause immune dysregulation and adrenal insufficiency, which may exacerbate CIRCI and prolong shock. Existing sepsis research has been predominantly conducted in high-income countries and has largely excluded people living with HIV or TB. Therefore, there is a need to better understand sepsis and CIRCI pathophysiology in the context of specific regional host and pathogen characteristics. In this narrative review, we explored the pathophysiology of sepsis in sub-Saharan Africa including the existing literature on the immune response to sepsis and the prevalence of adrenal insufficiency in patients with HIV and TB, with a focus on the implications for corticosteroid management. We found a compelling need to further evaluate corticosteroids for the treatment of sepsis in Africa.


  • Breaks in the Cascade of Care: Evidence to Shift From Facility-Based Screening of Household Contacts of People With Tuberculosis in Rural Tanzania

    by Ghassan Ilaiwy, Scott K Heysell, Saning’o Lukumay, Domitila Agustino, Paulo Mejan, Kusulla Simeon, Estomih Mduma, Tania A Thomas


  • Open Access

    Tuberculosis Infection in People Living with Human Immunodeficiency Virus: Challenges and Solutions

    by Ghassan Ilaiwy, Tania A. Thomas

  • Meropenem-vaborbactam restoration of first-line drug efficacy and comparison of meropenem-vaborbactam-moxifloxacin versus BPaL MDR-TB regimen

    by Sanjay Singh, Tawanda Gumbo, Jan-Willem Alffenaar, Gunavanthi D. Boorgula, Prem Shankar, Tania A. Thomas, Keertan Dheda, Lesibana Malinga, Prithvi Raj, Santosh Aryal, et al.


  • Duration of Symptoms Prior to Pediatric and Adolescent Tuberculosis Diagnosis and Its Impact on Schooling in Tanzania: A Mixed Methods Study

    by Ghassan Ilaiwy, Saning’o Lukumay, Domitila Augustino, Paulo Mejan, Rehema Bukhay, Museveni Justine, Cornel Massong, Prakruti Rao, Kristen Petros de Guex, Herman Pfaeffle, et al.

    : At least a third of tuberculosis (TB) cases remain undiagnosed, disproportionately so in children and adolescents, which is hampering global elimination goals. Prolonged symptom duration presents a high-risk scenario for childhood TB in endemic areas, but the prolonged period of symptoms and its impact on educational attainment are rarely documented. Using a mixed method approach, we aimed to quantify the duration of respiratory symptoms and describe their impact on education among children from a rural area of Tanzania. We used data from a prospectively enrolled cohort of children and adolescents aged 4–17 years in rural Tanzania at the start of active TB treatment. We report on the cohort’s baseline characteristics and explore the correlation between duration of symptoms and other variables. In-depth qualitative interviews were designed on the basis of a grounded theory approach to explore the impact of TB on educational attainment among school-aged children. In this cohort, children and adolescents diagnosed with TB experienced symptoms for a median of 85 days (interquartile range: 30, 231 days) prior to treatment initiation. In addition, 56 participants (65%) had a TB exposure in the household. Of the 16 families with school-aged children who were interviewed, 15 (94%) reported a significant negative impact of TB on the schooling of their children. Children in this cohort experienced a long duration of TB symptoms; the extent of illness impacted absenteeism at school. Screening initiatives for households affected by TB may lead to a shortened duration of symptoms and may minimize the impact on school attendance.


  • Open Access

    Decision Analytic Modeling for Global Clinical Trial Planning: A Case for HIV-Positive Patients at High Risk for Mycobacterium tuberculosis Sepsis in Uganda

    by Jessica Keim-Malpass, Scott K. Heysell, Tania A. Thomas, Jennifer M. Lobo, Stellah G. Mpagama, Conrad Muzoora, Christopher C. Moore

    Sepsis is a significant cause of mortality among people living with human immunodeficiency virus (HIV) in sub-Saharan Africa. In the planning period prior to the start of a large multi-country clinical trial studying the efficacy of the immediate empiric addition of anti-tuberculosis therapy to standard-of-care antibiotics for sepsis in people living with HIV, we used decision analysis to assess the costs and potential health outcome impacts of the clinical trial design based on preliminary data and epidemiological parameter estimates. The purpose of this analysis was to highlight this approach as a case example where decision analysis can estimate the cost effectiveness of a proposed clinical trial design. In this case, we estimated the impact of immediate empiric anti-tuberculosis (TB) therapy versus the diagnosis-dependent standard of care using three different TB diagnostics: urine TB-LAM, sputum Xpert-MTB/RIF, and the combination of LAM/Xpert. We constructed decision analytic models comparing the two treatment strategies for each of the three diagnostic approaches. Immediate empiric-therapy demonstrated favorable cost-effectiveness compared with all three diagnosis-dependent standard of care models. In our methodological case exemplar, the proposed randomized clinical trial intervention demonstrated the most favorable outcome within this decision simulation framework. Applying the principles of decision analysis and economic evaluation can have significant impacts on study design and clinical trial planning.


  • Open Access

    Impact of COVID-19 on diagnosis of tuberculosis, multidrug-resistant tuberculosis, and on mortality in 11 countries in Europe, Northern America, and Australia. A Global Tuberculosis Network study

    by Joanitah Nalunjogi, Sergio Mucching-Toscano, Jean Pierre Sibomana, Rosella Centis, Lia D'AMbrosio, Jan-Willem Alffenaar, Justin Denholm, François-Xavier Blanc, Sergey Borisov, Edvardas Danila, et al.